jyseleca
gilead sciences ireland uc, galapagos nv - filgotinib maleate - liðagigt, liðagigt - Ónæmisbælandi lyf - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
lamisil krem 10 mg/g
karo healthcare ab - terbinafinum hýdróklóríð - krem - 10 mg/g
felodipine alvogen (felodipin ratiopharm) forðatafla 2,5 mg
alvogen ehf. - felodipinum inn - forðatafla - 2,5 mg
felodipine alvogen (felodipin ratiopharm) forðatafla 10 mg
alvogen ehf. - felodipinum inn - forðatafla - 10 mg
felodipine alvogen (felodipin ratiopharm) forðatafla 5 mg
alvogen ehf. - felodipinum inn - forðatafla - 5 mg
montelukast ratiopharm (montelukast teva) filmuhúðuð tafla 10 mg
teva sweden ab - montelukastum natríum - filmuhúðuð tafla - 10 mg
livostin nefúði, dreifa 0,5 mg/ml
mcneil sweden ab - levocabastinum hýdróklóríð - nefúði, dreifa - 0,5 mg/ml
livostin augndropar, dreifa 0,5 mg/ml
mcneil sweden ab - levocabastinum hýdróklóríð - augndropar, dreifa - 0,5 mg/ml
vermox tafla 100 mg
mcneil sweden ab - mebendazolum inn - tafla - 100 mg
vermox mixtúra, dreifa 20 mg/ml
mcneil sweden ab - mebendazolum inn - mixtúra, dreifa - 20 mg/ml